Development of pH-Dependent Nanospheres for Nebulisation- In vitro Diffusion, Aerodynamic and Cytotoxicity Studies

Abstract

The aim of this work was to evaluate the in vitro performance of nebulized nanosuspension formulation when nebulized using ultrasonic nebulizer. The present investigation deals with successful formulation of Beclomethasone dipropionate loaded HPMCP nanospheres prepared by solvent evaporation technique using PEG 400 as a stabilizer. Beclomethasone dipropionate is a water insoluble drug molecule was encapsulated in HPMCP nanospheres to have pH dependent solubility at basic pH for targeted drug delivery in lung and studied for in vitro cytotoxicity and immediate release capability. The synthesized nanospheres were characterized through drug excipient compatibility, surface topography; mean particle size , zeta potential, PDI, entrapment efficiency and drug loading, in vitro diffusion, aerodynamic, in vitro cytotoxicity and stability studies. The mean particle size and PDI of the optimized batch (F1) had 197.6±0.40 nm and 0.324 ±0.35, respectively. The % entrapment efficiency and % drug loading was found to be 86.56±1.32 and 8.30±0.27, respectively. The optimized batch F1 showed % cumulative drug release 94.77±0.24 at 1 h. The formulation showed cell viability up to 91.28%. It can be concluded that, Beclomethasone dipropionate loaded HPMCP nanospheres was found to be safe, stable with significant increase in solubility and bypass the liver.

Key words

Drug delivery - Anti-asthma / COPD drugs - Pulmonary & respiratory pharmacology

• References

• 1 Schueepp KG, Devadason SG, Roller C, Minocchieri S, Moeller A, Hamacher J, Wildhaber JH. Aerosol delivery of nebulised Budesonide in young children with asthma. Resp Med 2009; 103: 1738-1745
• 2 Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56: 588-599
• 3 Sutradhar KB, Khatun S, Luna IP. Increasing possibilities of nanosuspension. J Nanotech 2013; 1-12
• 4 Sakagami M, Kinoshita W, Sakon K, Sato J, Makino Y. Mucoadhesive Beclomethasone microspheres for powder inhalation: Their pharmacokinetics and pharmacodynamics evaluation. J. Controlled Release 2002; 80: 361-367
• 5 Maxwell R, Eckhardt S. Beclomethasone Dipropionate, Springer Science, Business Media Drug Discovery. New York: Humana Press; 1990: 349-362
• 6 Brogden RN, Heel RC, Speight TM, Avery GS. Beclomethasone dipropionate: A reappraisal of its pharmacodynamic properties and therapeutic efficacy after decade of use in asthma and rhinitis. Drugs 1984; 28: 99-126
• 7 Farmer IS, Middle M, Savic J, Perrink V, Herdman MJ. Therapeutic equivalence of inhaled Beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the easy breathe inhaler for the treatment of paediatric asthma. Respir Med 2000; 94: 57-63
• 8 Wim M, Aalderen V, Sprikkelman A. Inhaled corticosteroids in childhood asthma: The story continues. Eur J Pediatr 2011; 170: 709
• 9 Ostrander KD, Bosch HW, Bondanza DM. An in vitro assessment of a nano crystal Beclomethasone dipropionate colloidal dispersion via ultrasonic nebulisation. Eur J Pharm Biopharm 1999; 48: 207-215
• 10 Douglas S, Gardenhire B. Corticosteroids in Respiratory Care. In: Elsevier publication Ninth (ed.) Rau’s Respiratory Care Pharmacology. 2015: 190-192
• 11 Arzu A. Jet, ultrasonic and mesh nebulizers: An evaluation of nebulizers for better clinical outcomes. Eur J Pulmonol 2014; 16: 1-7
• 12 Hess DR. Nebulizers: Principles and Performance. Resp Care 2000; 45: 609-622
• 13 McCallion ONM, Taylor KMG, Bridges PA, Thomas M, Taylor AJ. Jet nebulisers for pulmonary drug delivery. Int J Pharm 1996; 130: 1-11
• 14 Thomas SHL, Langford JA, George RDJ, Geddes DM. Improving the efficiency of drug administration with jet nebulisers. Lancet 1988; 331: 126
• 15 Herna N, Trejo N, Kayser O, Steckel H, Muller R. Characterization of nebulized Buparvaquone nanosuspensions—effect of nebulization technology. J Drug Target 2005; 13: 499-507
• 16 Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Abo M, Kasahara K. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in elderly asthmatics. Drug Res (Stuttg) 2018; 68: 38-44
• 17 Yang JZ, Young AL, Chiang P, Thurston A, Pretzer DK. Fluticasone and Budesonide nanosuspensions for pulmonary delivery: Preparation, characterization, and pharmacokinetic studies. J Pharm Sci 2008; 97: 4869-4878
• 18 Chiang P, Alsup J, Heyde B. Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res. Lett 2009; 4: 254-261
• 19 Lestari M, Muller R, Moschwitzer J. Systematic screening of different surface modifiers for the production of physically stable nanosuspensions. J Pharm Sci 2014; DOI
• 20 Wua ZM, Zhou L, Guo XD. HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm 2012; 425: 1-8
• 21 Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev 2006; 58: 1688-1713
• 22 Gilania K, Najafabadia AR, Barghi M. Aerosolisation of Beclomethasone dipropionate using spray dried lactose/polyethylene glycol carriers. Eur J Pharm Biopharm 2004; 58: 595-606
• 23 Knopp MM, Tajber L, Tian Y, Olesen NE, Jones D. Comparative study of different methods for the prediction of drug-polymer solubility. Mol Pharm 2015; 09: 3408-3419
• 24 Sahib MN, Darwis Y, Peh KK, Abdulamir SA. Incorporation of Beclomethasone dipropionate into polyethylene glycol-diacyl lipid micelles as a pulmonary delivery system. Drug Dev Res 2012; 73: 90-105
• 25 Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. A new powder design method to improve inhalation efficiency of Pranlukast hydrate dry powder aerosol by surface modification with HPMC phthalate nanospheres. Pharm Res 1998; 15: 1748-1752
• 26 Ige PP, Bariya RK, Gattani SG. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids and Surfaces B: Biointerfaces 2013; 108: 366-373
• 27 Jain S, Mittal A, Jain A, Mahajan RR, Singh D. Cyclosporin- a loaded PLGA nanoparticle: Preparation, optimization, in vitro characterization and stability studies. Curr Nanosci 2010; 6: 1-10
• 28 Maalej CJ, Andrieu V, Elaissari A, Fessi H. Beclomethasone loaded lipidic nanocarriers for pulmonary drug delivery: Preparation, characterization and in vitro drug release. J Nanosci Nanotechnol 2011; 11: 1841-1851
• 29 Chassot JM, Riba D, Elita Silveir EF, Grünspan LD. Beclomethasone dipropionate-loaded polymeric nanocapsules: Development, in vitro cytotoxicity, and in vivo evaluation of acute lung injury. J Nanosci Nanotechnol 2015; 15: 855-864
• 30 Ige PP, Bachhav NA, Mahajan HS, Nerkar PP, Gattani SG. Atorvstatin-loaded oleic acid nanoglobules for oral administration: In vitro characterization and biopharmaceutical evaluation. Current Nanoscience 2013; 9: 202-210
• 31 Ige PP, Solanki ND. Preparation and in vitro-in vivo evaluation of surface-modified poly (lactide-co-glycolide) nanoparticles as controlled release carriers for flutamide delivery. Journal of Microencapsulation 2015; 32: 231-239
• 32 Kudarha RR, Dhas NL, Pandey A, Belgamwar VS, Ige PP. Box–Behnken study design for optimization of bicalutamide-loaded nanostructured lipid carrier: Stability assessment. Pharmaceutical Development and Technology 2015; 20: 608-618